MA35662B1 - Administration of a nedd8 activating enzyme inhibitor and hypomethylation agent - Google Patents
Administration of a nedd8 activating enzyme inhibitor and hypomethylation agentInfo
- Publication number
- MA35662B1 MA35662B1 MA37066A MA37066A MA35662B1 MA 35662 B1 MA35662 B1 MA 35662B1 MA 37066 A MA37066 A MA 37066A MA 37066 A MA37066 A MA 37066A MA 35662 B1 MA35662 B1 MA 35662B1
- Authority
- MA
- Morocco
- Prior art keywords
- administration
- enzyme inhibitor
- activating enzyme
- treatment
- hypomethylation agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des procédés pour le traitement du cancer dans des patients en besoin reconnu d'un tel traitement. Les procédés comprennent l'administration à un tel patient d'un inhibiteur de nae ou d'un sel pharmaceutiquement acceptable de celui-ci, tel que le sulfamate de ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-indén-1-ylamino)-7h-pyrrolo[2,3 d]pyrimidin 7-yl)-2-hydroxycyclopentyl)méthyle (mln4924) ou le sulfamate de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-chloro-2 méthoxy-2,3-dihydro-1h-indén-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}-méthyle (i-216), et un agent d'hypométhylation ou un sel pharmaceutiquement acceptable de celui-ci, tel que l'azacitidine ou la décitabine. L'invention porte également sur des médicaments destinés à être utilisés dans le traitement du cancer.The present invention relates to methods for the treatment of cancer in patients in need recognized for such treatment. The methods include administering to such a patient an nae inhibitor or a pharmaceutically acceptable salt thereof, such as ((1s, 2s, 4r) -4- (4 - ((1s -2,3-dihydro-1H-inden-1-ylamino) -7H-pyrrolo [2,3 d] pyrimidin-7-yl) -2-hydroxycyclopentyl) methyl (mln4924) or the sulfonate of {(1 s, 2s, 4r) -4 - [(6 - {[(1r, 2s) -5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl] amino} pyrimidin-4-yl) oxy] -2 hydroxycyclopentylmethyl (1-216), and a hypomethylation agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. The invention also relates to medicaments for use in the treatment of cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555049P | 2011-11-03 | 2011-11-03 | |
| PCT/US2012/063382 WO2013067396A2 (en) | 2011-11-03 | 2012-11-02 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35662B1 true MA35662B1 (en) | 2014-11-01 |
Family
ID=48193039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37066A MA35662B1 (en) | 2011-11-03 | 2014-05-26 | Administration of a nedd8 activating enzyme inhibitor and hypomethylation agent |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8980850B2 (en) |
| EP (1) | EP2773360B1 (en) |
| JP (2) | JP6231988B2 (en) |
| KR (1) | KR101987861B1 (en) |
| CN (1) | CN104245699B (en) |
| AU (1) | AU2012321106C1 (en) |
| BR (1) | BR112014010699B1 (en) |
| CA (1) | CA2854461C (en) |
| EA (1) | EA028380B1 (en) |
| ES (1) | ES2668272T3 (en) |
| GE (1) | GEP20196940B (en) |
| HK (1) | HK1201733A1 (en) |
| IL (1) | IL232353B (en) |
| MA (1) | MA35662B1 (en) |
| MX (1) | MX357835B (en) |
| MY (1) | MY176125A (en) |
| PL (1) | PL2773360T3 (en) |
| SG (1) | SG11201401895WA (en) |
| TN (1) | TN2014000194A1 (en) |
| TR (1) | TR201807342T4 (en) |
| UA (1) | UA114414C2 (en) |
| WO (1) | WO2013067396A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2562245C2 (en) | 2009-05-14 | 2015-09-10 | Милленниум Фармасьютикалз, Инк. | (1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-d]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE HYDROCHLORIDE |
| WO2013028832A2 (en) * | 2011-08-24 | 2013-02-28 | Millennium Pharmaceuticals, Inc. | Inhibitors of nedd8-activating enzyme |
| EP2764866A1 (en) * | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP2996773B1 (en) | 2013-05-14 | 2020-09-16 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| CA2919296A1 (en) * | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
| MX2016013027A (en) | 2014-04-04 | 2017-05-23 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer. |
| CN103948590A (en) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | NEDD8 (neural precursor cell-expressed developmentally downregulated 8)activating enzyme inhibitor and medical application thereof |
| WO2017066611A1 (en) * | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| WO2018218119A1 (en) * | 2017-05-25 | 2018-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases |
| JP2020534331A (en) * | 2017-09-21 | 2020-11-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ((1S, 2S, 4R) -4- {4-[(1S) -2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-D] pyrimidin-7-yl} -2-Hydroxycyclopentyl) Co-crystal form of methyl sulfamate, its formulation and use |
| WO2020106876A2 (en) * | 2018-11-20 | 2020-05-28 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| EP3938050A1 (en) | 2019-03-15 | 2022-01-19 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115007323B (en) * | 2022-06-17 | 2024-01-23 | 中南大学 | Method for inhibiting pyrite floatation in minerals |
| WO2024012414A1 (en) * | 2022-07-11 | 2024-01-18 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| RS52458B (en) | 2005-02-04 | 2013-02-28 | Millennium Pharmaceuticals Inc. | Inhibitors of e1 activating enzymes |
| CA2639924C (en) | 2006-02-02 | 2017-01-10 | Millennium Pharmaceuticals, Inc. | Purinyl-and pyrrolo[2,3-d]pyrimidinyl cyclopentyl compounds and their use as inhibitors of e1 activating enzymes |
| WO2008019124A1 (en) * | 2006-08-08 | 2008-02-14 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| EP2211870A1 (en) | 2007-11-01 | 2010-08-04 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| JP2011513274A (en) * | 2008-02-26 | 2011-04-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Antitumor combination comprising a morpholinyl anthracycline derivative and a demethylating agent |
| ES2969144T3 (en) | 2008-05-15 | 2024-05-16 | Celgene Corp | Oral formulations of cytidine analogues and methods of use thereof |
| CA2725295C (en) * | 2008-06-09 | 2016-11-08 | Cyclacel Limited | Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
| KR101755725B1 (en) * | 2009-03-23 | 2017-07-07 | 암비트 바이오사이언시즈 코포레이션 | Methods of treatment using combination therapy |
| RU2562245C2 (en) | 2009-05-14 | 2015-09-10 | Милленниум Фармасьютикалз, Инк. | (1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-d]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE HYDROCHLORIDE |
| CA2825152A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| US9125884B2 (en) | 2011-11-01 | 2015-09-08 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
-
2012
- 2012-11-02 ES ES12844799.2T patent/ES2668272T3/en active Active
- 2012-11-02 CA CA2854461A patent/CA2854461C/en not_active Expired - Fee Related
- 2012-11-02 MX MX2014005323A patent/MX357835B/en active IP Right Grant
- 2012-11-02 WO PCT/US2012/063382 patent/WO2013067396A2/en active Application Filing
- 2012-11-02 UA UAA201405842A patent/UA114414C2/en unknown
- 2012-11-02 SG SG11201401895WA patent/SG11201401895WA/en unknown
- 2012-11-02 JP JP2014540146A patent/JP6231988B2/en active Active
- 2012-11-02 TR TR2018/07342T patent/TR201807342T4/en unknown
- 2012-11-02 AU AU2012321106A patent/AU2012321106C1/en not_active Ceased
- 2012-11-02 PL PL12844799T patent/PL2773360T3/en unknown
- 2012-11-02 EP EP12844799.2A patent/EP2773360B1/en active Active
- 2012-11-02 EA EA201400539A patent/EA028380B1/en not_active IP Right Cessation
- 2012-11-02 KR KR1020147014236A patent/KR101987861B1/en active IP Right Grant
- 2012-11-02 BR BR112014010699-1A patent/BR112014010699B1/en not_active IP Right Cessation
- 2012-11-02 US US13/667,641 patent/US8980850B2/en active Active
- 2012-11-02 CN CN201280062112.9A patent/CN104245699B/en active Active
- 2012-11-02 GE GEAP201213483A patent/GEP20196940B/en unknown
- 2012-11-02 MY MYPI2014001239A patent/MY176125A/en unknown
-
2014
- 2014-04-29 IL IL232353A patent/IL232353B/en active IP Right Grant
- 2014-04-30 TN TNP2014000194A patent/TN2014000194A1/en unknown
- 2014-05-26 MA MA37066A patent/MA35662B1/en unknown
-
2015
- 2015-01-23 US US14/603,717 patent/US20150366886A1/en not_active Abandoned
- 2015-03-06 HK HK15102294.2A patent/HK1201733A1/en unknown
-
2017
- 2017-10-20 JP JP2017203560A patent/JP2018009035A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35662B1 (en) | Administration of a nedd8 activating enzyme inhibitor and hypomethylation agent | |
| Raap et al. | Pathophysiology of itch and new treatments | |
| LU93321I2 (en) | IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| Durgam et al. | Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study | |
| Kraus et al. | Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance | |
| DE602006004844D1 (en) | PYRROLOPYRIMIDINE USE AS PROTEIN KINASE INHIBITORS | |
| RU2011115406A (en) | NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THERAPY, AND ALSO APPLICATION OF THE PYRIMIDINE DERIVATIVES IN THE PRODUCTION OF A MEDICINE FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE | |
| MX2021012478A (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor. | |
| AU2005253776A8 (en) | Screening methods using c-Abl, Fyn and Syk in combination with tau protein | |
| MA29799B1 (en) | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | |
| DE602006021776D1 (en) | AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS | |
| JO2755B1 (en) | Use of 2-6 (3- amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrilfor treating diabetes,cancer , autoimmune disorders and hiv infection | |
| DE602007007985D1 (en) | AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINO-PRIMIDINES | |
| MA31305B1 (en) | WEEKLY ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | |
| AU2006258038A1 (en) | Synergistic modulation of FLT3 kinase using aminopyrimidines kinase modulators | |
| NO20076219L (en) | Pharmaceutical formulation with apomorphine for buccal administration | |
| CL2007001178A1 (en) | Fused compounds derived from tetrahydro [1,2,4] triazole [4,3-a] pyrimidine, metabotropic glutamate receptor modulators (mglur5); intermediary compounds; composition and pharmaceutical combination that includes them; and its use in the preparation of medications to treat gastroesophageal diseases, anxiety and pain. | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| MA30779B1 (en) | PEDIATRIC TABLETS OF CAPECITABINE | |
| WO2018005519A3 (en) | Cancer treatment combinations | |
| MA31264B1 (en) | Methods of treating cancer comprising administering human il-18 in combination | |
| AR062114A1 (en) | MODULATORS OF THE ACTIVITY OF THE CHEMIOKIN RECEIVER, CRYSTAL FORMS AND PROCESSES. | |
| MX2021000349A (en) | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies. | |
| BR112021016795A8 (en) | ADMINISTRATION OF JUICE ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS | |
| Hojjat-Farsangi | Small Molecule inhibitors: suitable drugs for targeted-based cancer therapy |